Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors

British Journal of Pharmacology

Volumn 126, Issue 4, 1999, Pages 1057-1065

  Vanderheyden, P M L ^a   Fierens, F L P ^a   De Backer, J P ^a   Fraeyman, N ^b   Vauquelin, G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Angiotensin II; Antagonist; AT1 receptors; Calcium transients; Candesartan; CHO cells; Extracellular acidification; Inositol trisphosphate; Insurmountable; Surmountable

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BOVINE SERUM ALBUMIN; CANDESARTAN; CELL SURFACE RECEPTOR; INOSITOL PHOSPHATE; IRBESARTAN; LITHIUM CHLORIDE; LOSARTAN; LOSARTAN POTASSIUM;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0032942443     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702398     Document Type: Article

References (36)

1. Arunlakshana, O. & Schild, H.O. (1959). Some quantitative use of drugs antagonists. Br. J. Pharmacol., 14, 48-52.
2. Balmforth, A.J., Lee, A.L., Warburton, P., Donnelly, D. & Ball, S.G. (1997). The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane Helices III and VII. J. Biol. Chem., 272, 4245-4251.
3. Beauchamp, H.T., Chang, R.S.L., Siegl, P.K.S. & Gibson, R.E. (1994) In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency. J. Pharm. Exp. Ther., 272, 612-618.
4. 1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther., 265, 826-834.
5. 1 receptor antagonist. Br. J. Pharmacol., 114, 1117-1124.
6. 1b receptors: pharmacological and functional requirements. FEBS Lett., 349, 365-370.
7. Crozat, A., Penhoat, A & Saez, J.M. (1986). Processing of angiotensin II (A-II) and (sar1,Ala8)A-II by cultured bovine adrenocortical cells. Endocrinol., 118, 2312-2318.
8. De Chaffoy De Courcelles, D., Leysen, J.E., Roevens P. & Van Belle, H. (1986). The Serotonin-S2 Receptor: A receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Dev. Res., 8, 173-178.
9. Dickinson, K.E., Cohen, R.B., Skwish, S., Delaney, C.L., Serafino, R.P., Poss, M.A., Gu, Z., Ryono, D.E., Moreland, S. & Powell, J.R (1994). BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br. J. Pharmacol., 113, 179-189.
10. Furuta, H., Guo, D.-F. & Inagami, T. (1992). Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem. Biophys. Res. Cumm., 183, 8-13.
11. Gaddum, J.H., Hameed, K.A., Hathaway, D.E. & Stephens, F.F. (1955). Quantitative studies on antagonists for 5-hydroxytryptamine. Q. J. Exp. Physiol., 40, 49-74.
12. Gero, A. (1983). Desensitization, two-state receptors and pharmacological parameters. J. Theoret Biol., 103, 137-161.
13. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
14. 2 receptors: evidence for selective sorting of receptor and ligand. Mol. Endocrinol., 11, 1266-1277.
15. Hodges, J.C., Hamby, J.M. & Blankley, C.J. (1992). Angiotensin II receptor binding inhibitors. Drugs Future, 17, 575-593.
16. Koh, E., Morimoto, S., Tomita, J., Rakugi, H., Jiang, B., Inoue, T., Nabata, T., Fukuo, K. & Ogihara, T. (1994). Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 23, 175-179.
17. Limbird, L.L. (1996). Methods for characterization of receptors based on receptor-mediated responses in tissue or intact cell preparations. In Cell Surface Receptors: A Short Course on Theory and Methods. ed. Limbird, L.L. pp. 27-60. Boston/ Dordrecht/London: Kluwer Academic Publishers.
18. Liu, Y.J., Shankley, N.P., Welsh, N.J. & Black, J.W. (1992). Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action. Br. J. Pharmacol., 106, 233-241.
19. McConnell, H.M., Owicki, J.R., Parce, J.W., Miller D.L., Baxter, G.T., Wada, H.G. & Pitchford, S. (1992). The cytosensor microphysiometer: biological applications of silicon technology. Science, 257, 1906-1912.
20. Mochizuki, S., Sato, T., Furata, K., Hase, K., Ohkura, Y., Fukai, C., Kosakai, K., Wakabayashi, S. & Tomiyama, A. (1995). Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J. Cardiovasc. Pharmacol., 25, 22-29.
21. Noda, M., Shibouta, Y., Inada, Y., Ojima, M., Wada, T., Sanada, T., Kubo, K., Kohara, Y., Naka, T. & Nishikawa, K. (1993). Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem. Pharmacol., 46, 311-318.
22. Ojima, M., Inada, Y., Shibouta, Y., Wada, T., Sanada, T., Kubo, K. & Nishikawa, K. (1997). Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. J. Pharmacol., 319, 137-146.
23. Olins, G.M., Chen, S.T., McMahon, E., Palomo, M.A. & Reitz, D.B. (1994). Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629. Mol. Pharmacol., 47, 115-120.
24. Panek, R.L., Lu, G.H., Overhisser, R.W., Major, T.C., Hodges, J.C. & Taylor, D.G. (1995). Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J. Pharm. Exp. Ther., 273, 753-761.
25. 1 receptor. J. Biol. Chem., 270, 1493-1496.
26. 1 receptor antagonist. J. Cardiovasc. Pharmacol., 25, 354-360.
27. 1 receptor antagonist. Br. J. Pharmacol., 107, 1173-1180.
28. Robertson, M.J., Dougall, I.G., Harper, D., McKechnie, K.C.W. & Leff, P. (1994). Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol. Sci., 15, 364-369.
29. Seeuwen, K, Lagarde, A & Pouyssegur, J. (1988). Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide-specific phospholipase C. EMBO J., 7, 161-168
30. Shibouta, Y., Inada, Y., Ojima, M., Wada, T., Noda, M., Sanada, T., Kubo, K., Kohara, Y., Naka, T. & Nishikawa, K. (1993). Pharmacological profile of a highly potent & long-acting Angiotensin II receptor antagonist, 2-Ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylic Acid (CV-11974), and its prodrug, (±)-1-(Cyclohexyloxycarbonyloxy)-ethyl 2-Ethoxy-1-[[2′-(1H-tetrazol-5-yl)biohenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J. Pharm. Exp. Ther., 266, 114-120.
31. Timmermans, P.B., Benfield, P., Chiu, A.T., Herblin, W.F. & Wong, P.C. (1992). Angiotensin II receptors and functional correlates. Am. J. Hypertens., 5, 221S-235S.
32. Timmermans, P.B.M.W.M., Wong, P.C., Chiu, A.T. & Herblin, W.F. (1991). Nonpeptide angiotensin II receptor antagonists. Trends. Pharmacol. Sci., 12, 55-62.
33. 2+ and pH, Putative signals for the control of cell growth. Life Sci., 38, 2269-2276.
34. Wienen, W., Mauz, A.B.M., Van Meel, J.C.A. & Entzeroth, M. (1992). Different type of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol. Pharmacol., 41, 1081-1088.
35. Wong, P.C., Price, A.W., Chiu, A.T., Duncia, J.V., Carini, D.J., Wexler, R., Johnson, A. & Timmermans, P.B.M.W.M. (1990). Nonpeptide angiotensin receptor antagonists. XL Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensice agent. J. Pharmacol. Exp. Ther., 255, 211-217.
36. Zhang, J.C., Van Meel, A., Pfaffendorf, M. & Van Zwieten, P. (1993). Different types of angiotensin II receptor antagonism Induced by BIBS 222 in the rat portal vein and rabbit aorta; the influence of receptor reserve. J. Pharmacol. Exp. Ther., 269, 509-514.